Summary
Bristol Myers Squibb Company (BMY) announced on March 1st and 2nd, 2022, updates regarding their previously announced cash tender offers to purchase outstanding notes. These offers encompass notes issued by BMY itself and its wholly-owned subsidiary, Celgene Corporation. The company has provided early participation results and announced an upsizing of these offers, indicating a proactive approach to managing its debt obligations. Furthermore, BMY has confirmed the early settlement and the accepted amounts along with the pricing terms for these tender offers. This move suggests that the company is taking advantage of favorable market conditions or strategic financial management to refinance or reduce its debt. Investors should note that these tender offers are governed by the terms outlined in the Offer to Purchase dated February 15, 2022, and any subsequent amendments.
Key Highlights
- 1BMY announced early participation results for its cash tender offers on March 1, 2022.
- 2The company announced an upsizing of these cash tender offers.
- 3Early settlement and pricing terms for the tender offers were announced on March 2, 2022.
- 4The tender offers include notes issued by Bristol Myers Squibb and its subsidiary, Celgene Corporation.
- 5These actions are related to the company's management of its outstanding debt obligations.
- 6The offers are subject to the terms detailed in the Offer to Purchase dated February 15, 2022.